Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Medtronic Global Holdings €6.25 billion notes offering
Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of €6.25…
ADC Therapeutics $204 million SEC-registered offering
Davis Polk advised ADC Therapeutics SA on its SEC-registered offering of 6,000,000 common shares for total gross…
Zai Lab HK$5.94 billion secondary listing and IPO on the HKEX
Davis Polk advised Zai Lab Limited in connection with its secondary listing and initial public offering on the Hong Kong…
GoodRx Holdings $1.3 billion IPO
Davis Polk advised the representatives of the several underwriters in connection with the $1.3 billion initial public…
Omnicell $575 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in a Rule 144A offering by Omnicell, Inc. of $575 million…
Humanigen stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with…
American Well $853 million IPO and NYSE listing
Davis Polk advised American Well Corporation (“Amwell”) in connection with its initial public offering of 47,405,555 shares…
Natera $287.5 million follow-on offering
Davis Polk advised the representatives of the several underwriters in connection with the follow-on offering of 4,791…
Gilead Sciences $21 billion acquisition of Immunomedics
Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The…
MDLIVE $50 million private placement
Davis Polk advised MDLIVE Inc. in connection with its private placement of approximately $50 million in shares of its Series…